<DOC>
	<DOCNO>NCT00207116</DOCNO>
	<brief_summary>The purpose study predict response Erbitux single agent patient Non Small Cell Lung Cancer</brief_summary>
	<brief_title>An Exploratory Pharmacogenomic Study Monotherapy Erbitux Subjects With Metastatic Non Small Cell Lung Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Measurable disease tumor available biopsy Life expectancy least 3 month Known documented brain metastasis prior Cetuximab therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Metastatic Non Small Cell Lung Cancer</keyword>
</DOC>